Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
MER Indicator |
MER description |
Target Fiscal Year |
Target |
C2.1.D |
By Age: <15 |
2015 |
2,835 |
C2.1.D |
By Age: 15+ |
2015 |
639 |
C2.1.D |
By Age/Sex: <15 Female |
2015 |
1,440 |
C2.1.D |
By Age/Sex: <15 Male |
2015 |
1,395 |
C2.1.D |
By Age/Sex: 15+ Female |
2015 |
363 |
C2.1.D |
By Age/Sex: 15+ Male |
2015 |
276 |
C2.1.D |
By Sex: Female |
2015 |
1,803 |
C2.1.D |
By Sex: Male |
2015 |
1,671 |
C2.1.D |
Number of HIV-positive individuals receiving a minimum of one clinical service |
2015 |
3,474 |
C2.1.D |
Sum of Age disaggregates |
2015 |
3,474 |
C2.1.D |
Sum of Age/Sex disaggregates |
2015 |
3,474 |
C2.1.D |
Sum of Sex disaggregates |
2015 |
3,474 |
C2.4.D |
Number of HIV-positive individuals receiving a minimum of one clinical service |
2015 |
3,474 |
C2.4.D |
Number of HIV-positive patients who were screened for TB in HIV care or treatment setting |
2015 |
3,149 |
C2.5.D |
Number of HIV-positive individuals receiving a minimum of one clinical service |
2015 |
3,474 |
C2.5.D |
Number of HIV-positive patients in HIV care who started TB treatment |
2015 |
14 |
CARE_CURR |
Age/sex: <1 Female |
2015 |
74 |
CARE_CURR |
Age/sex: <1 Male |
2015 |
84 |
CARE_CURR |
Age/sex: 1-4 Female |
2015 |
348 |
CARE_CURR |
Age/sex: 1-4 Male |
2015 |
324 |
CARE_CURR |
Age/sex: 10-14 Female |
2015 |
584 |
CARE_CURR |
Age/sex: 10-14 Male |
2015 |
528 |
CARE_CURR |
Age/sex: 15-19 Female |
2015 |
300 |
CARE_CURR |
Age/sex: 15-19 Male |
2015 |
242 |
CARE_CURR |
Age/sex: 20-24 Female |
2015 |
28 |
CARE_CURR |
Age/sex: 20-24 Male |
2015 |
25 |
CARE_CURR |
Age/sex: 25-49 Female |
2015 |
29 |
CARE_CURR |
Age/sex: 25-49 Male |
2015 |
9 |
CARE_CURR |
Age/sex: 5-9 Female |
2015 |
437 |
CARE_CURR |
Age/sex: 5-9 Male |
2015 |
459 |
CARE_CURR |
Age/sex: 50+ Female |
2015 |
3 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
1,442 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
1,396 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
360 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
276 |
CARE_CURR |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2015 |
3,474 |
CARE_CURR |
Sum of Age/Sex disaggregates |
2015 |
3,474 |
CARE_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
3,474 |
CARE_NEW |
Age/sex: <1 Female |
2015 |
44 |
CARE_NEW |
Age/sex: <1 Male |
2015 |
45 |
CARE_NEW |
Age/sex: 1-4 Female |
2015 |
31 |
CARE_NEW |
Age/sex: 1-4 Male |
2015 |
15 |
CARE_NEW |
Age/sex: 10-14 Female |
2015 |
10 |
CARE_NEW |
Age/sex: 10-14 Male |
2015 |
11 |
CARE_NEW |
Age/sex: 15-19 Male |
2015 |
2 |
CARE_NEW |
Age/sex: 5-9 Female |
2015 |
21 |
CARE_NEW |
Age/sex: 5-9 Male |
2015 |
27 |
CARE_NEW |
Aggregated Age/sex: <15 Female |
2015 |
105 |
CARE_NEW |
Aggregated Age/sex: <15 Male |
2015 |
97 |
CARE_NEW |
Aggregated Age/sex: 15+ Female |
2015 |
2 |
CARE_NEW |
Aggregated Age/sex: 15+ Male |
2015 |
2 |
CARE_NEW |
Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |
2015 |
206 |
CARE_NEW |
Sum of Age/sex disaggregates |
2015 |
206 |
CARE_NEW |
Sum of Aggregated Age/sex disaggregates |
2015 |
206 |
CARE_SITE |
By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole |
2015 |
9 |
CARE_SITE |
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services |
2015 |
9 |
CARE_SITE |
Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole |
2015 |
9 |
CARE_SITE |
Sum of Numerator Site Support Type disaggregates |
2015 |
9 |
CARE_SITE |
Total number of PEPFAR supported sites providing clinical care services |
2015 |
9 |
CARE_SITE_den |
Sum of Denominator Site Support Type disaggregates |
2015 |
9 |
FN_SITE |
By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition |
2015 |
9 |
FN_SITE |
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services |
2015 |
9 |
FN_SITE |
Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition |
2015 |
9 |
FN_SITE |
Sum of Numerator Support Type disaggregates |
2015 |
9 |
FN_SITE |
Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services |
2015 |
9 |
FN_SITE_den |
Sum of Denominator Support Type disaggregates |
2015 |
9 |
HTS_TST |
Age/sex: <1 Female |
2015 |
39 |
HTS_TST |
Age/sex: <1 Female |
2015 |
39 |
HTS_TST |
Age/sex: <1 Male |
2015 |
44 |
HTS_TST |
Age/sex: <1 Male |
2015 |
42 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
83 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
83 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
72 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
72 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
125 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
124 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
154 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
154 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
175 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
175 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
125 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
125 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
289 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
289 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
259 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
259 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
215 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
215 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
248 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
248 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
122 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
122 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
189 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
189 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
71 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
74 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
68 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
68 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
369 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
457 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
752 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
700 |
HTS_TST |
Aggregated Age/sex: <15 Female |
2015 |
369 |
HTS_TST |
Aggregated Age/sex: <15 Male |
2015 |
457 |
HTS_TST |
Aggregated Age/sex: 15+ Female |
2015 |
752 |
HTS_TST |
Aggregated Age/sex: 15+ Male |
2015 |
700 |
HTS_TST |
By Test Result: Negative |
2015 |
2,087 |
HTS_TST |
By Test Result: Negative |
2015 |
2,123 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
2,278 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
2,278 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
2,278 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
2,278 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
826 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
826 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
1,452 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
1,452 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
2,278 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
2,278 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
2,278 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
2,278 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
191 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
155 |
OVC_ACC |
Age: <1 |
2015 |
158 |
OVC_ACC |
Age: 1-4 |
2015 |
672 |
OVC_ACC |
Age: 10-14 |
2015 |
774 |
OVC_ACC |
Age: 15-17 |
2015 |
880 |
OVC_ACC |
Age: 18+ |
2015 |
94 |
OVC_ACC |
Age: 5-9 |
2015 |
896 |
OVC_ACC |
Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services |
2015 |
3,474 |
OVC_ACC |
Sex: Female |
2015 |
1,803 |
OVC_ACC |
Sex: Male |
2015 |
1,671 |
OVC_ACC |
Sum of Age disaggregates |
2015 |
3,474 |
OVC_ACC |
Sum of Sex disaggregates |
2015 |
3,474 |
OVC_SERV |
Age: 1-4 |
2015 |
1,302 |
OVC_SERV |
Age: 10-14 |
2015 |
1,655 |
OVC_SERV |
Age: 15-17 |
2015 |
2,187 |
OVC_SERV |
Age: 18+ |
2015 |
3,089 |
OVC_SERV |
Age: 5-9 |
2015 |
1,367 |
OVC_SERV |
Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS |
2015 |
9,600 |
OVC_SERV |
Sex: Female |
2015 |
5,571 |
OVC_SERV |
Sex: Male |
2015 |
4,029 |
OVC_SERV |
Sum of Age disaggregates |
2015 |
9,600 |
OVC_SERV |
Sum of Sex disaggregates |
2015 |
9,600 |
PP_PREV |
Age/sex: 10-14 Female |
2015 |
652 |
PP_PREV |
Age/sex: 10-14 Male |
2015 |
614 |
PP_PREV |
Age/sex: 15-19 Female |
2015 |
491 |
PP_PREV |
Age/sex: 15-19 Male |
2015 |
435 |
PP_PREV |
Age/sex: 20-24 Female |
2015 |
53 |
PP_PREV |
Age/sex: 20-24 Male |
2015 |
60 |
PP_PREV |
Age/sex: 25-49 Female |
2015 |
1 |
PP_PREV |
Age/sex: 25-49 Male |
2015 |
2 |
PP_PREV |
Age/sex: 50+ Female |
2015 |
92 |
PP_PREV |
Age/sex: 50+ Male |
2015 |
6 |
PP_PREV |
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period |
2015 |
2,406 |
PP_PREV |
Sum of Age/Sex disaggregates |
2015 |
2,406 |
PP_PREV |
Total number of people in the target population |
2015 |
2,406 |
SI_HIS |
Existence of a national registry of health facilities that is updated annually |
2015 |
1 |
SI_HIS |
Full national facility list coordinated with PEPFAR |
2015 |
1 |
SI_ME |
Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model |
2015 |
1 |
SITE_SUPP |
By program area/support type: Care and Support Direct Service Delivery (DSD) |
2015 |
9 |
SITE_SUPP |
By program area/support type: Food and Nutrition Direct Service Delivery (DSD) |
2015 |
9 |
SITE_SUPP |
By program area/support type: General Population Prevention Direct Service Delivery (DSD) |
2015 |
9 |
SITE_SUPP |
By program area/support type: HTC Direct Service Delivery (DSD) |
2015 |
9 |
SITE_SUPP |
By program area/support type: Lab Direct Service Delivery (DSD) |
2015 |
2 |
SITE_SUPP |
By program area/support type: OVC Direct Service Delivery (DSD) |
2015 |
9 |
SITE_SUPP |
By program area/support type: TB/HIV Direct Service Delivery (DSD) |
2015 |
9 |
SITE_SUPP |
By program area/support type: Treatment Direct Service Delivery (DSD) |
2015 |
9 |
SITE_SUPP |
Number of unique sites supported by PEPFAR |
2015 |
9 |
TB_ART |
Age: 0-4 |
2015 |
20 |
TB_ART |
Age: 15+ |
2015 |
42 |
TB_ART |
Age: 5-14 |
2015 |
78 |
TB_ART |
Aggregated Age: <15 |
2015 |
98 |
TB_ART |
Aggregated Age: 15+ |
2015 |
42 |
TB_ART |
Female |
2015 |
70 |
TB_ART |
Known HIV-positive |
2015 |
84 |
TB_ART |
Male |
2015 |
70 |
TB_ART |
Newly tested |
2015 |
56 |
TB_ART |
Sum of Aggregated Age disaggregates |
2015 |
140 |
TB_ART |
Sum of Sex disaggregates |
2015 |
140 |
TB_ART |
Sum of Test Status disaggregates |
2015 |
140 |
TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period |
2015 |
140 |
TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |
2015 |
140 |
TB_ARTSITE |
By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units |
2015 |
9 |
TB_ARTSITE |
By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period |
2015 |
9 |
TB_ARTSITE |
Sum of Numerator Site Support Type disaggregates |
2015 |
9 |
TB_ARTSITE |
The number of PEPFAR-supported TB basic management units |
2015 |
9 |
TB_ARTSITE |
The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period |
2015 |
9 |
TB_ARTSITE_den |
Sum of Denominator Site Support Type disaggregates |
2015 |
9 |
TB_SCREEN |
Age: <1 |
2015 |
158 |
TB_SCREEN |
Age: 1-4 |
2015 |
671 |
TB_SCREEN |
Age: 10-14 |
2015 |
1,112 |
TB_SCREEN |
Age: 15-19 |
2015 |
543 |
TB_SCREEN |
Age: 20-24 |
2015 |
53 |
TB_SCREEN |
Age: 25-49 |
2015 |
38 |
TB_SCREEN |
Age: 5-9 |
2015 |
896 |
TB_SCREEN |
Age: 50+ |
2015 |
3 |
TB_SCREEN |
Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 |
2015 |
2,837 |
TB_SCREEN |
Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ |
2015 |
637 |
TB_SCREEN |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2015 |
3,474 |
TB_SCREEN |
Sex: Female |
2015 |
1,803 |
TB_SCREEN |
Sex: Male |
2015 |
1,671 |
TB_SCREEN |
Sum of Age disaggregates |
2015 |
3,380 |
TB_SCREEN |
Sum of Aggregated Age disaggregates |
2015 |
3,474 |
TB_SCREEN |
Sum of Sex disaggregates |
2015 |
3,474 |
TB_SCREEN |
The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period |
2015 |
3,474 |
TX_CURR |
Age/Sex: <1 Female |
2015 |
10 |
TX_CURR |
Age/Sex: <1 Male |
2015 |
6 |
TX_CURR |
Age/Sex: 1-4 Female |
2015 |
182 |
TX_CURR |
Age/Sex: 1-4 Male |
2015 |
165 |
TX_CURR |
Age/Sex: 15+ Female |
2015 |
322 |
TX_CURR |
Age/Sex: 15+ Male |
2015 |
262 |
TX_CURR |
Age/Sex: 5-14 Female |
2015 |
841 |
TX_CURR |
Age/Sex: 5-14 Male |
2015 |
838 |
TX_CURR |
Aggregated Age/Sex: <1 Female |
2015 |
10 |
TX_CURR |
Aggregated Age/Sex: <1 Male |
2015 |
6 |
TX_CURR |
Aggregated Age/Sex: <15 Female |
2015 |
1,033 |
TX_CURR |
Aggregated Age/Sex: <15 Male |
2015 |
1,009 |
TX_CURR |
Aggregated Age/Sex: 15+ Female |
2015 |
322 |
TX_CURR |
Aggregated Age/Sex: 15+ Male |
2015 |
262 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
2,626 |
TX_CURR |
Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] |
2015 |
78 |
TX_CURR |
Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] |
2015 |
51 |
TX_CURR |
Sum of age/sex disaggregates |
2015 |
2,042 |
TX_CURR |
Sum of Aggregated Age/Sex <15 |
2015 |
2,042 |
TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2015 |
584 |
TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
2,626 |
TX_CURR_NGI |
Age/Sex: <1 Female |
2015 |
10 |
TX_CURR_NGI |
Age/Sex: <1 Male |
2015 |
6 |
TX_CURR_NGI |
Age/Sex: 1-4 Female |
2015 |
182 |
TX_CURR_NGI |
Age/Sex: 1-4 Male |
2015 |
165 |
TX_CURR_NGI |
Age/Sex: 15+ Female |
2015 |
322 |
TX_CURR_NGI |
Age/Sex: 15+ Male |
2015 |
262 |
TX_CURR_NGI |
Age/Sex: 5-14 Female |
2015 |
840 |
TX_CURR_NGI |
Age/Sex: 5-14 Male |
2015 |
839 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Female |
2015 |
10 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Male |
2015 |
6 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Female |
2015 |
1,033 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Male |
2015 |
1,009 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Female |
2015 |
322 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Male |
2015 |
262 |
TX_CURR_NGI |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
2,626 |
TX_CURR_NGI |
Sum of Age/Sex disaggregates |
2015 |
2,626 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex <15 |
2015 |
2,042 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex 15+ |
2015 |
584 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex disaggregates |
2015 |
2,626 |
TX_NEW |
Aggregated Grouping by Age: <1 Male |
2015 |
23 |
TX_NEW |
Aggregated Grouping by Age/Sex: <1 Female |
2015 |
23 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Female |
2015 |
69 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Male |
2015 |
68 |
TX_NEW |
By Age/Sex: <1 Female |
2015 |
9 |
TX_NEW |
By Age/Sex: <1 Male |
2015 |
9 |
TX_NEW |
By Age/Sex: 1-4 Female |
2015 |
12 |
TX_NEW |
By Age/Sex: 1-4 Male |
2015 |
11 |
TX_NEW |
By Age/Sex: 10-14 Female |
2015 |
23 |
TX_NEW |
By Age/Sex: 10-14 Male |
2015 |
22 |
TX_NEW |
By Age/Sex: 15-19 Female |
2015 |
14 |
TX_NEW |
By Age/Sex: 15-19 Male |
2015 |
12 |
TX_NEW |
By Age/Sex: 5-9 Female |
2015 |
13 |
TX_NEW |
By Age/Sex: 5-9 Male |
2015 |
12 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2015 |
137 |
TX_NEW |
Sum of Age/Sex disaggregates |
2015 |
137 |
TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2015 |
137 |
TX_RET |
Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
37 |
TX_RET |
Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
24 |
TX_RET |
Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
64 |
TX_RET |
Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
101 |
TX_RET |
Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
22 |
TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2015 |
123 |
TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2015 |
137 |
TX_RET_den |
Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
41 |
TX_RET_den |
Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
26 |
TX_RET_den |
Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
70 |
TX_RET_den |
Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
111 |
TX_RET_den |
Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
26 |
TX_SITE |
By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation |
2015 |
9 |
TX_SITE |
By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites |
2015 |
9 |
TX_SITE |
Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation |
2015 |
9 |
TX_SITE |
Sum of Numerator Site Support Type disaggregates |
2015 |
9 |
TX_SITE |
Total number of PEPFAR-supported ART sites |
2015 |
9 |
TX_SITE_den |
Sum of Denominator Site Support Type disaggregates |
2015 |
9 |